Venetoclax + navitoclax was well-tolerated without unexpected toxicity and with promising preliminary efficacy in heavily pre-treated patients with relapsed or refractory acute lymphoblastic leukaemia or lymphoblastic lymphoma (R/R B- and T-ALL or LL).
Prof. Elias Jabbour (University of Texas MS Anderson Cancer Centre, USA) presented the phase 1, multicentre, open-label, dose-escalation study , addressing the unmet need for new treatment options in R/R ALL and LL. The investigators hypothesised that BCL2 inhibitor venetoclax in combination with low-dose navitoclax (a BCL-XL inhibitor) could improve efficacy while minimising dose-limiting toxicities known to occur with standard-dose navitoclax monotherapy.
Patients (n=47, median age 29 years, median number of prior therapies was 4) received 400 mg venetoclax (weight-adjusted equivalent) daily, together with daily oral navito...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Nivolumab/brentuximab vedotin in R/R HL: good CMR rates Next Article
Microbiome predicts B-ALL predisposition »
Table of Contents: EHA 2020
Plasma Cell Dyscrasias
Bench-to-Bedside Science from the Presidential Symposium
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.